#1 Clinical Trials Search in Europe

Thiotepa

Thiotepa, an alkylating agent with potent antitumor and immunosuppressive properties, is being extensively studied in clinical trials for its efficacy in various cancer treatments and stem cell transplantation procedures. This article explores the ongoing research on Thiotepa’s use in different medical conditions, its potential benefits, and the challenges associated with its administration.

Table of Contents

What is Thiotepa?

Thiotepa is a powerful chemotherapy drug used in the treatment of various cancers and other serious medical conditions. It belongs to a class of drugs called alkylating agents, which work by damaging the DNA of cancer cells to stop them from growing and dividing[1]. Thiotepa is also known by other names, including:

  • N N’N’triethylenethiophosphoramide
  • Tepadina[2]

How Thiotepa Works

Thiotepa is an alkylating agent that works by creating cross-links in DNA strands. This process inhibits the synthesis of DNA, RNA, and proteins in cells, effectively stopping them from reproducing. Thiotepa is cell-cycle independent, meaning it can affect cells at any stage of their growth cycle[2]. One unique feature of Thiotepa is its ability to cross the blood-brain barrier, making it particularly useful in treating cancers that affect the central nervous system[3].

Conditions Treated with Thiotepa

Thiotepa is used to treat a variety of conditions, including:

  • Osteosarcoma: A type of bone cancer[1]
  • Lymphomas: Including Non-Hodgkin’s Lymphoma, Hodgkin’s Lymphoma, and Primary Central Nervous System Lymphoma (PCNSL)[4][5]
  • Central Nervous System Tumors[3]
  • Hematologic Malignancies: Cancers of the blood and bone marrow[6]
  • Non-malignant disorders: Such as bone marrow failure syndromes, hemoglobinopathies, and immune deficiencies[7]

How Thiotepa is Administered

Thiotepa is typically administered intravenously (through a vein) as part of a chemotherapy regimen. The dosage and schedule can vary depending on the specific condition being treated and the overall treatment plan. Some common administration methods include:

  • High-dose therapy followed by stem cell rescue (autologous stem cell transplantation)[1]
  • As part of a conditioning regimen before allogeneic hematopoietic stem cell transplantation[7]
  • In combination with other chemotherapy drugs, such as methotrexate, fludarabine, or melphalan[5][2]

The dose of Thiotepa can range from 5 mg/kg to 10 mg/kg, depending on the specific treatment protocol and the patient’s condition[7].

Potential Side Effects

Like all chemotherapy drugs, Thiotepa can cause side effects. Some of the most common side effects include:

  • Lowered blood cell counts: This can increase the risk of infection, bleeding, and fatigue
  • Gastrointestinal issues: Such as nausea, vomiting, and diarrhea
  • Mouth sores
  • Loss of appetite
  • Liver abnormalities
  • Hair loss
  • Fatigue
  • Skin rash[2]

Your healthcare team will monitor you closely for these side effects and may adjust your treatment or provide supportive care as needed.

Ongoing Research and Clinical Trials

Thiotepa continues to be studied in various clinical trials to improve its effectiveness and explore new applications. Some areas of ongoing research include:

  • Optimizing dosing and combination therapies for different types of cancers[5]
  • Investigating its use in reduced-intensity conditioning regimens for stem cell transplantation[7]
  • Studying its effectiveness in treating relapsed or refractory cancers[1]
  • Exploring its use in pediatric patients undergoing stem cell transplantation[6]

These ongoing studies aim to improve treatment outcomes and reduce side effects for patients receiving Thiotepa-based therapies.

Aspect Details
Primary uses Conditioning regimens for stem cell transplantation, treatment of various cancers
Cancer types studied Osteosarcoma, lymphomas, multiple myeloma, leukemia, central nervous system tumors
Administration Intravenous, often in combination with other chemotherapy drugs
Dosage range Varies by trial; examples include 5-10 mg/kg/day for 1-2 days
Key benefits Crosses blood-brain barrier, potent antitumor effects, immunosuppressive properties
Common side effects Lowered blood counts, increased infection risk, GI tract issues, fatigue
Research goals Optimize dosage, improve treatment outcomes, reduce toxicity, enhance disease eradication

FAQ

  • What is Thiotepa and how does it work? Thiotepa is an alkylating agent that produces cross-linking of DNA strands, leading to inhibition of DNA, RNA, and protein synthesis. It is cell-cycle independent and has potent antitumor and immunosuppressive properties.
  • In which medical conditions is Thiotepa being studied? Thiotepa is being studied in various conditions including osteosarcoma, lymphomas, multiple myeloma, leukemia, central nervous system tumors, and as part of conditioning regimens for stem cell transplantation in both malignant and non-malignant disorders.
  • What are the potential side effects of Thiotepa? Potential side effects of Thiotepa include lowering of white blood cell or platelet counts, increased risk of infection, bruising or bleeding, damage to the GI tract causing mouth sores, nausea, vomiting, and diarrhea. Other side effects may include loss of appetite, liver abnormalities, hair loss, swelling, fatigue, and skin rash.
  • How is Thiotepa administered in clinical trials? Thiotepa is typically administered intravenously, often in combination with other chemotherapy drugs. The dosage and schedule vary depending on the specific trial and condition being treated, ranging from single doses to multiple doses over several days.
  • What are researchers hoping to achieve with Thiotepa in clinical trials? Researchers are aiming to determine the optimal dosage and combination of Thiotepa with other drugs to improve treatment outcomes, reduce toxicity, enhance disease eradication, and improve survival rates in various cancer types and stem cell transplantation procedures.

Ongoing Clinical Trials on Thiotepa

  • Testing Stem Cell Transplant Methods and Medications Including Ruxolitinib and Blinatumomab for Children and Young Adults with Acute Lymphoblastic Leukemia

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Czechia Denmark Finland France Germany +3

  • Study on Stem Cell Transplantation and Immunotherapy with Rituximab, Dinutuximab Beta, and Drug Combination for Patients with High-Risk Relapsed Neuroblastoma

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study of olaparib and chemotherapy combination in stage III breast cancer patients with HER2-negative, hormone receptor impaired or deficient disease

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France The Netherlands

  • Study of Azacitidine and Drug Combination Before Stem Cell Transplantation in Patients with High-Risk Myelodysplastic Syndrome

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on High-Dose Chemotherapy with Cytarabine and Drug Combination for Elderly Patients with Primary CNS Lymphoma

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Germany

  • Study of drug combination therapy for high-risk medulloblastoma in patients over 3 years of age: carboplatin, cisplatin, cyclophosphamide, lomustine, temozolomide, thiotepa, vincristine

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland Germany +4

  • Study on High-Risk Neuroblastoma Treatment with Busulfan, Melphalan, and Drug Combination for Patients with Insufficient Metastatic Response

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +7

  • Study on Graft-Versus-Host Disease Prevention Using Cyclophosphamide and Methotrexate in Adults with Blood Cancer Undergoing Matched-Donor Transplant

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on CAR-T-cell Therapy with Rituximab and Ibrutinib for Patients with High-Risk Mantle Cell Lymphoma

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Germany The Netherlands Spain

  • Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using CPX-351, Gemtuzumab Ozogamicin, and a Drug Combination

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Czechia Germany Greece Italy Poland

Glossary

  • Alkylating agent: A type of chemotherapy drug that works by damaging the DNA of cancer cells, preventing them from dividing and multiplying.
  • Hematopoietic stem cell transplantation (HSCT): A procedure that replaces damaged or diseased bone marrow with healthy stem cells, which can develop into new, healthy blood cells.
  • Conditioning regimen: A combination of chemotherapy and/or radiation therapy given before stem cell transplantation to prepare the body for the new stem cells.
  • Graft-versus-host disease (GVHD): A complication that can occur after stem cell transplantation when the donor's immune cells attack the recipient's tissues.
  • Engraftment: The process by which transplanted stem cells start to produce new, healthy blood cells in the recipient's body.
  • Relapse: The return of cancer after a period of improvement or remission.
  • Osteosarcoma: A type of bone cancer that typically affects children and young adults.
  • Lymphoma: A type of cancer that affects the lymphatic system, part of the body's germ-fighting network.
  • Multiple myeloma: A cancer of plasma cells, a type of white blood cell that normally produces antibodies.
  • Leukemia: A group of blood cancers that usually begin in the bone marrow and result in high numbers of abnormal blood cells.

References

  1. https://clinicaltrials.gov/study/NCT00978471
  2. https://clinicaltrials.gov/study/NCT03342196
  3. https://clinicaltrials.gov/study/NCT00607984
  4. https://clinicaltrials.gov/study/NCT03346096
  5. https://clinicaltrials.gov/study/NCT06646211
  6. https://clinicaltrials.gov/study/NCT03609840
  7. https://clinicaltrials.gov/study/NCT03513328